Benitec Biopharma Inc. (BNTC) stock: price, suppliers, customers and institutional ownership
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.
No case yet. It builds on the next filing, report or 13F period.
Benitec Biopharma Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
High 11.27 at 11:15 am ET, low 10.98 at 3:30 pm ET.
Of the 6 companies Benitec Biopharma Inc. moves with most closely, none share its SEC classification.
Measured against 500 trading days of our own closes. Co-movement, not cause.
SIC 2834, Pharmaceutical Preparations, from each company's own filings. Largest first.
BNTC (Benitec Biopharma Inc.) has 0 disclosed suppliers and 0 disclosed customers, strongest disclosure first.
Select a tie for its filing sentence; select again to open the company. Nearer the centre, the more the filings disclose. Extended: satellites hang off single companies, not bundled sectors.
tall tick = annual report · 1 on record
86 managers report a position worth $443.3M between them, and 11 of them hold 80% of it.